Microarray and histopathological analysis of tumours: the future and the past?
The excitement surrounding the development of DNA microarray analysis and proteomics has raised questions about the role of these techniques in clinical practice and patient management. But how did the traditional methods of cancer diagnosis and prognosis develop, and how can high-throughput techniques contribute?
Lakhani
S R
SR
The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, UK. lakhani@icr.ac.uk
Ashworth
A
A
D018076:DNA, Complementary / Q000235:genetics; D004273:DNA, Neoplasm / Q000032:analysis*; D005544:Forecasting; D020869:Gene Expression Profiling; D006801:Humans; D009367:Neoplasm Staging; D009369:Neoplasms / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D009693:Nucleic Acid Hybridization; D020411:Oligonucleotide Array Sequence Analysis; D010336:Pathology / Q000639:trends*; D011379:Prognosis; D013382:Subtraction Technique
D018076:DNA, Complementary; D004273:DNA, Neoplasm